Shire And Foundation Fighting Blindness Announce Research Agreement

(RTTNews) - Shire plc (SHP.L, SHPG) and the Foundation Fighting Blindness announced a new agreement focused on furthering research for a treatment for autosomal dominant retinitis pigmentosa (adRP), a rare genetic disease that usually first occurs in late childhood or adolescence and is followed by the progressive loss of peripheral vision. There are no currently approved treatment options for adRP.

As part of the agreement, the Foundation Fighting Blindness and its research partners will provide Shire with expert knowledge and scientific background regarding adRP, as well as pertinent clinical information that could be useful in the development of a drug to treat adRP. The Foundation will also provide counsel as requested on the pre-clinical and/or clinical development of Shire compounds in development for the treatment of adRP.